Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
Author:
Affiliation:
1. Global Access, F. Hoffmann-La Roche, Basel, Switzerland
2. Cytel, Waltham, Massachusetts
3. The University of Texas MD Anderson Cancer Center, Houston
Publisher
American Medical Association (AMA)
Subject
General Medicine
Link
https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2786029/ramagopalan_2021_oi_210968_1635947858.16826.pdf
Reference30 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Sung;CA Cancer J Clin,2021
2. Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment.;Duma;Mayo Clin Proc,2019
3. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.;Kocher;Lung Cancer,2015
4. The biology and management of non-small cell lung cancer.;Herbst;Nature,2018
5. Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update.;Masters;J Clin Oncol,2015
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial;Science Bulletin;2024-02
2. Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis;Respiratory Medicine and Research;2023-11
3. Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements;Frontiers in Pharmacology;2023-07-13
4. bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer;eBioMedicine;2023-05
5. Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice;Journal of Clinical Medicine;2023-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3